xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
JACKSONVILLE, Fla. and IRVINE, Calif., Jan. 03, 2018 -- Espero BioPharma, a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced that Chairman and CEO Quang Pham will present at the Biotech Showcase 2018 on January 9th, 2018 at 11:45 AM PT / 2:45 PM ET. The conference will be held at the Hilton San Francisco Union Square in San Francisco.
Mr. Pham will provide a corporate overview and discuss the company’s late-stage product pipeline, including tecarfarin, Espero’s lead product candidate, and budiodarone, a potential best-in-class anti-arrhythmic agent for the treatment of refractory atrial fibrillation. Tecarfarin has the potential to be the oral anticoagulant therapy of choice for the 3.7 million patients in the United States who require anticoagulation with a Vitamin K antagonist such as warfarin, including patients with prosthetic heart valves, recurrent deep vein thrombosis or patients with chronic kidney disease, which complicates anticoagulant therapy.
The company plans to initiate The Tecarfarin for Anticoagulation Trial (TACT) in the second quarter of 2018 under an FDA-approved Special Protocol Assessment, with interim data anticipated in the fourth quarter of 2018 and filing of a New Drug Application with the U.S. Food and Drug Administration planned for 2020.
Espero also expects to initiate its third Phase 2 clinical trial of budiodarone in the second half of 2018. Budiodarone has been shown to be effective in significantly reducing atrial fibrillation burden and is being further evaluated as a novel anti-arrhythmic agent for the treatment of refractory atrial fibrillation.
About Espero BioPharma, Inc.
Espero BioPharma, Inc. is a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases. The Company has offices located in Jacksonville, FL and Irvine, CA. Additional information about Espero BioPharma is available at http://esperobio.com.
Investor Relations Contact
David Carey
Lazar Partners Ltd.
T: (212) 867-1768
[email protected]
Media Relations Contact
Glenn Silver
Lazar Partners Ltd.
T: (646) 871-8485
[email protected]
